Answers are grounded in this paper and cite their sources.
Highlights the potential of new antithrombotic agents targeting the tissue factor pathway, emphasizing the need for large clinical trials to demonstrate their efficacy.
Prevention of cardiovascular events should involve an adequate control of the risk factors (diabetes, blood pressure, hyperlipidemia, etc). Once the thrombotic complications occur, the invasive approaches combined with potent antithrombotic agents appears to have some advantage over fibrinolytic therapy. A need for better and more efficacious antithrombotics is indicated by the high incidence of thrombotic complications. Among the new antothrombotic agents, the inhibition of the TF pathway (inhibitors of factors VIIa, Xa or oral thrombin inhibitors) seems to be more promising. Their efficacy should be demonstrated in large and controlled clinical trials.
No takes yet. Share an insight, caveat, or question.
Roberto Corti (2002) conducted a review in Cardiovascular events and thrombotic complications. New antithrombotic agents (inhibitors of factors VIIa, Xa or oral thrombin inhibitors) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: